BACKGROUND: The most common, persistent concern among survivors of breast cancer is the fear that their disease will return, yet to the authors' knowledge, few interventions targeting fear of cancer recurrence (FCR) have been developed to date. The current pilot study examined the feasibility, acceptability, and preliminary efficacy of a home-delivered cognitive bias modification intervention to reduce FCR. The intervention, called Attention and Interpretation Modification for Fear of Breast Cancer Recurrence (AIM-FBCR), targeted 2 types of cognitive biases (ie, attention and interpretation biases). METHODS: A total of 110 survivors of breast cancer were randomized to receive 8 sessions of 1 of 2 versions of AIM-FBCR or a control condition program. Computer-based assessments of cognitive biases and a self-report measure of FCR were administered before the intervention, after the intervention, and 3 months after the intervention. RESULTS: Improvements in health worries (P = .019) and interpretation biases (rates of threat endorsement [P<.001] and reaction times for threat rejection [P = .007]) were found in those survivors who received AIM-FBCR compared with the control arm. Although only 26% of participants who screened into the study agreed to participate, the trial otherwise appeared feasible and acceptable, with 83% of those who initiated the intervention completing at least 5 of 8 sessions, and 90% reporting satisfaction with the computer-based program used. CONCLUSIONS: The results of the current pilot study suggest the promise of AIM-FBCR in reducing FCR in survivors of breast cancer. Future research should attempt to replicate these findings in a larger-scale trial using a more sophisticated, user-friendly program and additional measures of improvement in more diverse samples. Cancer 2017;123:1424-1433.
RCT Entities:
BACKGROUND: The most common, persistent concern among survivors of breast cancer is the fear that their disease will return, yet to the authors' knowledge, few interventions targeting fear of cancer recurrence (FCR) have been developed to date. The current pilot study examined the feasibility, acceptability, and preliminary efficacy of a home-delivered cognitive bias modification intervention to reduce FCR. The intervention, called Attention and Interpretation Modification for Fear of Breast Cancer Recurrence (AIM-FBCR), targeted 2 types of cognitive biases (ie, attention and interpretation biases). METHODS: A total of 110 survivors of breast cancer were randomized to receive 8 sessions of 1 of 2 versions of AIM-FBCR or a control condition program. Computer-based assessments of cognitive biases and a self-report measure of FCR were administered before the intervention, after the intervention, and 3 months after the intervention. RESULTS: Improvements in health worries (P = .019) and interpretation biases (rates of threat endorsement [P<.001] and reaction times for threat rejection [P = .007]) were found in those survivors who received AIM-FBCR compared with the control arm. Although only 26% of participants who screened into the study agreed to participate, the trial otherwise appeared feasible and acceptable, with 83% of those who initiated the intervention completing at least 5 of 8 sessions, and 90% reporting satisfaction with the computer-based program used. CONCLUSIONS: The results of the current pilot study suggest the promise of AIM-FBCR in reducing FCR in survivors of breast cancer. Future research should attempt to replicate these findings in a larger-scale trial using a more sophisticated, user-friendly program and additional measures of improvement in more diverse samples. Cancer 2017;123:1424-1433.
Authors: Jennie M Kuckertz; Nader Amir; Joseph W Boffa; Ciara K Warren; Susan E M Rindt; Sonya Norman; Vasudha Ram; Lauretta Ziajko; Jennifer Webb-Murphy; Robert McLay Journal: Behav Res Ther Date: 2014-09-16
Authors: Per Carlbring; Maria Apelstrand; Helena Sehlin; Nader Amir; Andreas Rousseau; Stefan G Hofmann; Gerhard Andersson Journal: BMC Psychiatry Date: 2012-06-25 Impact factor: 3.630
Authors: Allan 'Ben' Smith; Louise Sharpe; Belinda Thewes; Jane Turner; Jemma Gilchrist; Joanna E Fardell; Afaf Girgis; Stephanie Tesson; Joseph Descallar; Melanie L Bell; Jane Beith; Phyllis Butow Journal: Support Care Cancer Date: 2018-06-07 Impact factor: 3.603
Authors: Danielle Petricone-Westwood; Georden Jones; Brittany Mutsaers; Caroline Séguin Leclair; Christina Tomei; Geneviève Trudel; Andreas Dinkel; Sophie Lebel Journal: Int J Behav Med Date: 2019-02
Authors: Louise Sharpe; J Turner; J E Fardell; B Thewes; A B Smith; J Gilchrist; J Beith; A Girgis; S Tesson; S Day; K Grunewald; P Butow Journal: J Cancer Surviv Date: 2019-07-25 Impact factor: 4.442
Authors: Jeffrey L Birk; Robin Cumella; David Lopez-Veneros; Ammie Jurado; Emily K Romero; Amit Lazarov; Ian M Kronish Journal: Health Psychol Date: 2020-09 Impact factor: 4.267
Authors: Nina M Tauber; Mia S O'Toole; Andreas Dinkel; Jacqueline Galica; Gerry Humphris; Sophie Lebel; Christine Maheu; Gozde Ozakinci; Judith Prins; Louise Sharpe; Allan Ben Smith; Belinda Thewes; Sébastien Simard; Robert Zachariae Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544